Institutional investors are significantly increasing their positions in ImmunityBio. Strategic Investment Solutions boosted its stake by more than 2,300%. Mayflower Financial Advisory nearly doubled its existing holdings. This institutional activity is driving increased discussion among retail traders.
Stocktwits users speculate that a preliminary Q2 revenue update is imminent. Traders anticipate that sales for the bladder cancer drug Anktiva will exceed expectations. The stock is currently pacing for its worst weekly performance in over a month. Despite a modest two-session rally, the shares remain highly volatile ahead of upcoming performance metrics.